Endocrinology & Diabetes

This track provides an expanded examination of the autoimmune mechanisms underlying Type 1 diabetes (T1D). Discussions will include antigen presentation pathways, T-cell activation dynamics, beta-cell autoantigen profiles, and the role of environmental triggers such as viral infections and microbiome alterations. Experts will highlight the significance of genetic predispositions, autoantibody development timelines, and the silent progression of immune-mediated beta-cell destruction long before symptoms appear. Attendees will also explore how advanced immune assays and predictive biomarkers refine risk assessment and enable earlier interventions.

The prevention component emphasizes cutting-edge therapies aiming to preserve or restore beta-cell function. Presentations will review the latest immunomodulators, immune tolerance–inducing regimens, antigen-specific vaccines, and beta-cell protective biologics emerging from major clinical trials. There will also be a focus on population screening programs, early childhood monitoring strategies, and precision approaches for delaying or preventing disease onset. Collectively, this track sets the stage for understanding how immunology-driven insights can translate into the world’s first truly preventive strategies for Type 1 diabetes.

Type 2 diabetes (T2D) is increasingly recognized not as a single disease but as a spectrum of metabolic subtypes, each defined by unique biological signatures. This track delves into precision medicine frameworks that classify patients according to genetic variants, metabolic clusters, insulin-secretory capacities, lipid phenotypes, and gut microbiome patterns. Presentations will highlight how multi-omic profiling, AI-driven risk models, and longitudinal biomarker tracking are reshaping our understanding of patient heterogeneity. Attendees will see how precise stratification leads to optimized therapy selection and improved glycemic and cardiovascular outcomes.

The second part of this track translates precision concepts into practical clinical models. Participants will gain insights into pharmacogenomic-guided drug prescribing, personalized dietary algorithms, adaptive treatment pathways, and data-informed prediction of treatment response. The role of CGM analytics, digital twins, and predictive software in constructing personalized care plans will also be discussed. By integrating molecular insights with clinical decision-making, this track demonstrates how precision medicine is transforming T2D management into a more targeted, effective, and patient-centered discipline.

Diabetic complications remain a leading cause of morbidity, and this track offers a deep exploration of their underlying mechanisms and clinical implications. Experts will discuss microvascular and macrovascular injury pathways, oxidative stress, endothelial dysfunction, and advanced glycation end-product–mediated damage. A particular focus will be placed on diabetic nephropathy, including early biomarkers of kidney damage, the progression toward chronic kidney disease, and new therapeutic strategies that slow or reverse decline. Similarly, retinal complications—including retinopathy, macular edema, and neurodegeneration—will be covered with emphasis on emerging imaging tools and diagnostic technologies.

The cardiovascular segment addresses the intricate connections between diabetes, atherosclerosis, thrombosis, and heart failure. Presentations will highlight how novel medications such as SGLT2 inhibitors and GLP-1 RAs reshape risk profiles and improve organ outcomes beyond glycemic control. Attendees will also explore multidisciplinary management models, population-wide screening strategies, and personalized monitoring programs designed to detect complications earlier and improve long-term prognosis. This track provides a comprehensive view of how pathophysiology, technology, and advanced therapy converge to protect vital organs in diabetes care.

This track recognizes the strong interconnection between metabolic disease and cardiovascular risk, exploring how overlapping mechanisms such as insulin resistance, adiposity-driven inflammation, dyslipidemia, and hypertension potentiate one another. Attendees will learn how metabolic dysfunction accelerates endothelial injury, vascular stiffness, arrhythmias, and cardiomyopathy. Presentations will also examine the evolving understanding of NAFLD/NASH as a central cardio-metabolic driver, linking liver pathology to systemic metabolic and vascular consequences. Risk stratification tools, biomarker panels, and advanced imaging methods for early detection will be highlighted.

The second half of the track emphasizes integrated care models that treat diabetes and cardiovascular risk jointly rather than as separate entities. Experts will discuss optimal sequencing of therapies, combination drug strategies, lifestyle interventions, and guideline-based approaches to reduce morbidity. There will be special attention to sex-specific and ethnic variations in cardio-metabolic risk, enabling more individualized care. Ultimately, this track equips clinicians with a modern, holistic framework for managing complex patients who face overlapping metabolic and cardiovascular challenges.

This track provides an in-depth look at obesity as a complex chronic disease shaped by biological, behavioral, environmental, and socioeconomic factors. Presentations will examine the neuroendocrine regulation of appetite, adipose tissue remodeling, genetic predispositions, and the role of gut hormones in energy balance. Attendees will learn how emerging science in brown fat activation, metabolic rate variability, circadian rhythms, and microbiome composition contributes to weight gain or resistance to weight loss. The track also highlights innovations in obesity pharmacotherapy, including multi-hormonal agonists and combination agents that deliver clinically meaningful and sustained weight reduction.

The metabolic and bariatric surgery section will offer comprehensive insights into surgical interventions as transformative treatments for severe obesity and metabolic dysfunction. Experts will discuss procedure selection, preoperative assessment, postoperative nutritional management, and long-term surveillance for metabolic improvements beyond weight reduction. Sessions will cover how surgery impacts insulin sensitivity, hepatic steatosis, cardiovascular risk, and gut hormone signaling, providing a systems-level view of its metabolic benefits. Through clinical evidence, case-based learning, and procedure-specific updates, participants will develop a modern understanding of the evolving landscape of surgical and non-surgical obesity management.

This track explores the unique endocrine and metabolic challenges affecting children and adolescents, recognizing that early-life disruptions often shape lifelong health trajectories. Topics include pediatric obesity, early-onset Type 2 diabetes, congenital adrenal hyperplasia, growth hormone disorders, puberty-related abnormalities, and rare genetic endocrine syndromes. Presentations will highlight advances in neonatal screening, developmental endocrinology, and biomarkers for identifying metabolic abnormalities during growth. Attendees will also examine how family-centered interventions, school-based prevention programs, and digital monitoring tools are transforming pediatric endocrine care.

The second half focuses on transitioning pediatric patients into adult endocrine services—a period where many young individuals face gaps in care and increased health risks. Sessions will review best practices for adolescent engagement, psychosocial support, and age-appropriate management of chronic endocrine diseases such as T1D and thyroid disorders. Emerging technologies including pediatric-specific insulin delivery systems, wearable devices, and tele-endocrinology applications will also be featured. This track provides clinicians with a comprehensive framework for supporting metabolic and hormonal health throughout childhood and adolescence.

Gestational diabetes mellitus (GDM) affects maternal and fetal outcomes in profound ways, and this track examines its pathophysiology, screening methods, and clinical management strategies. Experts will discuss insulin resistance in pregnancy, placental hormone interactions, genetic predispositions, and metabolic adaptations that can predispose women to glucose intolerance. The track also highlights global variability in screening practices, risk prediction models, and the evolving debate on universal versus selective testing. Attendees will learn about personalized nutrition therapies, safe pharmacological options, and emerging digital tools for improving glycemic control during pregnancy.

The maternal-fetal component explores how maternal metabolic status influences fetal development, birth outcomes, and long-term child health, including risks for obesity, insulin resistance, and Type 2 diabetes later in life. Presentations will cover fetal monitoring, growth assessment, and prevention of complications such as preeclampsia, macrosomia, and postpartum metabolic decline. Long-term management strategies for women with prior GDM—including postpartum screening and preventive interventions—will be emphasized. This track equips clinicians with evidence-based frameworks to deliver comprehensive care across preconception, pregnancy, and postpartum phases.

Endocrine oncology encompasses a diverse spectrum of hormone-producing tumors, ranging from thyroid and adrenal malignancies to pituitary adenomas, neuroendocrine tumors, and pancreatic endocrine neoplasms. This track explores the molecular signatures, genomic alterations, and signaling pathways that drive tumor initiation and progression. Presentations will delve into diagnostic advances, including high-resolution imaging, functional nuclear medicine scans, and circulating tumor markers that enable earlier and more precise detection. Attendees will also gain insights into tumor classification systems, risk stratification tools, and evolving criteria for surgical and nonsurgical management.

The therapeutic portion highlights advances in targeted treatments, immunotherapy, radionuclide therapy, and precision surgical techniques that significantly improve outcomes for endocrine cancers. Experts will present real-world case studies illustrating the complexities of managing hormone hypersecretion syndromes, metastatic disease, and hereditary tumor syndromes such as MEN1 and MEN2. The track will also explore multidisciplinary approaches integrating endocrinology, oncology, nuclear medicine, genetics, and surgery—offering a comprehensive understanding of modern endocrine tumor management.

This track encompasses a wide range of disorders involving three of the most critical endocrine glands: the thyroid, adrenal, and pituitary. Presentations will cover hypothyroidism, hyperthyroidism, thyroiditis, adrenal insufficiency, Cushing’s syndrome, primary aldosteronism, pituitary adenomas, and growth and prolactin hormone abnormalities. Speakers will discuss diagnostic strategies using hormonal assays, dynamic stimulation tests, imaging modalities, and genomic tools that refine disease classification and personalize treatment decisions. Emphasis will also be placed on disease mechanisms, receptor signaling abnormalities, and long-term management considerations.

The track continues with updates on new therapeutic strategies, including advanced hormone replacement formulations, minimally invasive surgical approaches, targeted drug therapies, and biologics for autoimmune endocrine conditions. Challenging clinical cases will illustrate atypical presentations, treatment resistance, and overlapping endocrine pathologies. Attendees will leave with enhanced skills in diagnosis, risk assessment, and integrated management of complex thyroid, adrenal, and pituitary disorders that require nuanced clinical decision-making.

This track explores hormonal regulation across the reproductive lifespan, focusing on menstrual disorders, polycystic ovary syndrome (PCOS), infertility, menopause, hypogonadism, and hormone-related clinical syndromes. Presentations will analyze the intricate signaling pathways controlling ovulation, gonadal development, sex steroid production, and reproductive metabolic interactions. Attendees will examine how endocrine abnormalities affect fertility potential, pregnancy outcomes, menstrual health, and long-term metabolic risks in both men and women. Advanced diagnostic tools—including hormone profiling, imaging technologies, and fertility biomarkers—will also be highlighted.

The second part emphasizes therapeutic innovations and integrative care models. Experts will discuss personalized hormone therapies, assisted reproductive technologies, male reproductive endocrinology advancements, and lifestyle-based interventions for improving hormonal balance. Sessions will also explore gender-specific variations, reproductive aging, hormonal contraception, and the endocrine aspects of menopause and andropause. This track provides a deep understanding of how hormonal health influences overall well-being, fertility, metabolic function, and quality of life across different populations.

Genetic and genomic sciences are revolutionizing the diagnosis and management of endocrine diseases. This track highlights advances in next-generation sequencing, polygenic risk scoring, gene expression analysis, and functional genomics that uncover hereditary predispositions to diabetes, thyroid disorders, obesity, adrenal syndromes, and rare metabolic diseases. Presenters will examine how pathogenic variants influence cellular pathways, endocrine organ development, and metabolic homeostasis. Case studies will demonstrate the role of genomic testing in early diagnosis, surveillance, and risk prediction.

The clinical application section explores how precision genomics is shaping modern endocrine practice. Discussions will include genetic counseling, targeted therapies for mutation-specific conditions, ethical considerations of genomic medicine, and evolving guidelines for screening families with hereditary endocrine tumor syndromes. Attendees will gain insights into genotype–phenotype correlations, novel gene discoveries, and the integration of multi-omic data into personalized treatment strategies. This track equips clinicians and researchers with the tools needed to incorporate genomic science into everyday endocrine care.

This track examines the latest developments in biomarker discovery and diagnostic technologies that enhance the accuracy, speed, and precision of endocrine disease identification. Experts will discuss novel blood-based biomarkers, urinary assays, digital phenotyping tools, and multi-analyte panels for conditions such as diabetes, thyroid dysfunction, adrenal disorders, and metabolic syndrome. Presentations will highlight the role of omics-driven discovery—including proteomics, metabolomics, and lipidomics—in identifying early pathological signatures and predicting therapeutic response.

The second part explores state-of-the-art diagnostic innovations such as point-of-care testing, advanced endocrine imaging, AI-assisted interpretation systems, and continuous physiological monitoring through wearable sensors. Attendees will learn how these tools improve early detection, help track disease progression, and support personalized treatment decisions. By integrating molecular insights with digital diagnostics, this track showcases how technology-driven precision medicine is reshaping the future of endocrine evaluation

This track offers a comprehensive review of current and emerging therapies for diabetes management. Presentations will highlight advancements in oral agents, GLP-1 receptor agonists, SGLT2 inhibitors, dual and triple incretin therapies, and new insulin analogs designed for faster, safer, and more predictable glucose control. Experts will analyze mechanism-of-action insights, comparative efficacy data, safety profiles, and treatment algorithms that optimize glycemic targets while minimizing hypoglycemia and long-term complications.

The technology and devices segment focuses on cutting-edge insulin delivery systems, pump-based therapies, closed-loop platforms, and minimally invasive monitoring devices. Discussions will address patient selection, personalization of drug/device combinations, and strategies for integrating pharmacological and technological therapies into routine clinical workflows. This track equips healthcare professionals with a deep understanding of the rapidly evolving therapeutic landscape, supporting evidence-based decision-making and improved patient outcomes.

This track highlights the scientific and technological breakthroughs transforming insulin delivery across varying patient populations. Presentations will cover ultra-rapid formulations, stabilized insulin molecules, glucose-responsive “smart insulins,” and long-acting analogs engineered for 24-hour coverage with reduced variability. Experts will explore the biochemical modifications that improve absorption, maintain stability, and enhance pharmacokinetic predictability, enabling more physiological insulin replacement strategies. Discussions will also include formulation advances that improve warmth resistance, simplify storage, and support global accessibility.

The second part focuses on novel delivery platforms, including patch pumps, micro-needle devices, wearable injectors, and fully automated insulin delivery systems. Speakers will address usability studies, patient adherence trends, engineering improvements, and regulatory considerations for next-generation devices. The track also explores future directions such as implantable insulin depots, nanoparticle carriers, and sensor-integrated delivery technologies that bring diabetes care closer to true glycemic automation. Through scientific updates and practical insights, participants will gain a comprehensive view of the innovations shaping the future of insulin therapy.

This track focuses on the evolution of continuous glucose monitoring (CGM) and digital diabetes ecosystems that are reshaping real-time metabolic management. Presentations will cover sensor accuracy, calibration-free technologies, predictive analytics, trend-based guidance, and interoperability with insulin pumps and smart devices. Experts will discuss how CGM empowers patients through real-time insights, reduces glycemic variability, and supports individualized treatment decisions. Case studies will highlight clinical outcomes, patient-reported experiences, and advancements in sensor longevity and user comfort.

The digital tools component explores mobile applications, cloud-based dashboards, algorithm-driven coaching platforms, and remote patient monitoring systems. Discussions will examine the integration of behavioral nudges, telemedicine workflows, data-sharing frameworks, and digital biomarkers that guide therapeutic adjustments. Attendees will learn how digital ecosystems improve adherence, support clinicians in population-level management, and enable proactive, data-informed care models. This track offers a complete view of how CGM and digital innovation are redefining modern diabetes management.

Artificial intelligence and data-driven approaches are opening new frontiers in endocrine research and clinical practice. This track explores machine-learning applications in diagnosis, decision support, outcome prediction, and risk stratification for diabetes, thyroid disorders, obesity, and metabolic diseases. Presentations will highlight advancements in image analysis, digital phenotyping, data fusion from wearable sensors, and predictive models derived from large clinical datasets. Attendees will understand how big data enables earlier detection of complications, personalized therapy plans, and automated clinical workflows.

The digital health segment addresses real-world deployment of AI-enabled systems, regulatory considerations, bias mitigation strategies, and integration into electronic health records. Experts will discuss the ethical dimensions of algorithmic medicine and the future of fully virtual endocrine care pathways. With demonstrations of cutting-edge tools and case-based discussions, this track equips participants with practical knowledge of how AI and predictive analytics can transform the delivery of endocrine and metabolic healthcare.

This track explores the structural, financial, and policy-level factors shaping diabetes and endocrine healthcare worldwide. Presentations will examine healthcare financing models, reimbursement structures, cost-effectiveness analyses, and resource allocation for medications, technologies, and screening programs. Experts will discuss the economic burdens of diabetes complications, productivity loss, and long-term societal costs, offering insights for policymakers and global health organizations. Attendees will gain an understanding of how evidence-based policymaking can expand access to essential diagnostic and therapeutic tools.

The systems component covers integrated care pathways, national diabetes strategies, workforce capacity, and the design of value-based care models. Discussions will highlight policy innovations such as national digital registries, risk-based screening frameworks, and scalable community health programs. Best practices from different countries will demonstrate how systemic reforms improve outcomes, reduce disparities, and enhance the sustainability of endocrine care systems. This track provides a strategic perspective for leaders working at the intersection of healthcare delivery and public policy.

This track examines the evidence-based role of lifestyle interventions in preventing and managing metabolic disorders. Presenters will discuss nutritional science, meal composition, glycemic load management, macronutrient optimization, and personalized dietary strategies for diabetes and obesity. Sessions will also explore the impact of physical activity, stress regulation, circadian alignment, and sleep quality on metabolic outcomes. Emphasis will be placed on behavior change science, cultural adaptation of interventions, and models for long-term adherence.

The second section highlights emerging dietary approaches, microbiome-targeted nutrition, plant-forward patterns, and metabolic flexibility. Experts will evaluate the effectiveness of structured lifestyle programs, digital coaching, and community-based metabolic health models. Practical clinical strategies—such as motivational interviewing, lifestyle prescriptions, and multidisciplinary counseling—will be showcased. This track equips clinicians with a robust understanding of how lifestyle medicine integrates with pharmacological and technological therapies to deliver holistic endocrine care.

This track addresses inequities in access to endocrine and diabetes care across diverse regions and populations. Speakers will examine social determinants of health, geographic disparities, affordability challenges, and barriers facing underserved communities. Presentations will analyze global variation in insulin availability, CGM adoption, essential diagnostics, and workforce distribution. The track also highlights international collaborations, capacity-building initiatives, and community-powered programs that aim to bridge health gaps.

The equity-focused session emphasizes culturally sensitive care models, gender considerations, indigenous health frameworks, and strategies for improving self-management resources in low-resource settings. Experts will share evidence on how policy-level interventions, technology-driven outreach, and global partnerships can transform access to care. Through case studies and international perspectives, attendees will gain a comprehensive understanding of the challenges and solutions shaping equitable endocrine healthcare worldwide.

This track focuses on the design and implementation of proactive strategies aimed at identifying metabolic and endocrine disorders before the onset of irreversible complications. Presenters will explore population-level screening frameworks, risk-scoring models, genetic predisposition tools, and community-based outreach programs for early detection of diabetes, thyroid dysfunction, metabolic syndrome, and endocrine tumors. Emphasis will be placed on biomarkers, point-of-care diagnostics, digital screening platforms, and targeted prevention strategies tailored to high-risk groups.

The second section highlights innovative clinical pathways that integrate lifestyle interventions, early pharmacotherapy, and digital monitoring tools to reduce progression from preclinical states to overt disease. Case studies will illustrate the impact of early detection on long-term outcomes and healthcare costs, while policy experts will address opportunities and barriers in scaling screening initiatives across various health systems. Attendees will gain a comprehensive understanding of evidence-based preventive approaches and their role in reshaping the future of endocrine care.

Translational endocrinology bridges fundamental research with clinical application, and this track highlights breakthroughs that are accelerating this transition. Sessions will explore mechanistic studies of hormone signaling, cell–receptor interactions, metabolic regulation, and endocrine organ physiology. Researchers will present early-stage discoveries in stem cell biology, tissue regeneration, gene editing, and molecular therapeutics that hold promise for redefining the management of diabetes, obesity, thyroid disease, and rare endocrine disorders.

The clinical translation segment examines how these discoveries are converted into therapies, diagnostics, and medical technologies. Presentations will cover translational pipelines, model validation, regulatory pathways, and early-phase clinical testing. Examples of successful bench-to-bedside advancements—including regenerative therapies, smart hormone formulations, and targeted metabolic interventions—will be showcased. This track offers attendees a comprehensive view of how cutting-edge laboratory science forms the foundation for future clinical endocrinology.

This track provides a deep dive into the evolving landscape of clinical trials and regulatory frameworks guiding the development of endocrine therapies, medical devices, and diagnostics. Presentations will discuss trial design, recruitment approaches, endpoint selection, real-world evidence integration, and adaptive study methodologies tailored for metabolic and hormonal disorders. Experts will cover regulatory expectations for new drug applications, device approvals, biosimilar development, and safety monitoring protocols.

The second part highlights global regulatory harmonization, post-market surveillance, and ethical considerations in trial conduct. Sessions will examine patient-centric trial models, diversity and inclusion in study populations, digital trial platforms, and decentralized monitoring technologies. Case-based discussions will illustrate lessons learned from recent endocrine clinical trials, while industry experts will offer insights into submission strategies and regulatory innovation. This track equips participants with a robust understanding of the processes that bring endocrine breakthroughs from research to market.

This track emphasizes the importance of patient empowerment and personalized engagement in chronic endocrine care. Presentations will explore strategies that enhance communication, shared decision-making, health literacy, and behavioral adherence among individuals living with diabetes, thyroid disorders, obesity, and other metabolic conditions. Experts will discuss psychological and emotional dimensions of endocrine disease, including the role of stress, stigma, mental health, and social support systems.

The self-management component highlights digital coaching programs, remote support platforms, lifestyle interventions, and culturally adaptive care models that improve patient autonomy and long-term outcomes. Sessions will introduce person-centered care frameworks integrating pharmacotherapy, nutrition, exercise, and psychosocial interventions. By combining clinical evidence with practical tools, this track provides a roadmap for transforming traditional care models into collaborative, supportive, and individualized endocrine management systems.

This track addresses the growing need for a well-prepared endocrine workforce capable of managing the expanding global burden of metabolic diseases. Presentations will focus on competency-based medical education, updated endocrinology curricula, simulation-based training, interprofessional learning environments, and innovative teaching models for trainees and practicing clinicians. Attendees will explore strategies to incorporate digital learning, case-based modules, and hands-on procedural training into modern endocrine education.

The workforce development segment examines recruitment challenges, retention strategies, practice-ready skill development, and global disparities in endocrinology specialists. Discussions will cover leadership training, research capacity building, mentorship frameworks, and the use of tele-endocrinology to expand service reach in underserved regions. This track provides educators, program directors, and healthcare leaders with actionable insights to strengthen the future of the endocrine workforce.

Environmental endocrinology has rapidly evolved as a critical area of research, particularly as global exposure to endocrine-disrupting chemicals (EDCs) continues to rise. This track investigates the biological, molecular, and systemic effects of environmental chemicals—including plastics, pesticides, heavy metals, microplastics, and industrial pollutants—on hormonal function and metabolic health. Delegates will explore how EDCs mimic, block, or alter hormone signaling pathways involved in metabolism, growth, reproduction, and glucose homeostasis. Special emphasis will be placed on vulnerable populations such as children, pregnant women, and individuals with preexisting endocrine conditions, who may experience amplified health impacts.

Sessions will also cover environmental epigenetics, transgenerational metabolic disorders, and real-world exposure assessment methods, including biomonitoring and environmental surveillance technologies. Experts will discuss policy frameworks, regulatory actions, and public health strategies aimed at reducing exposure, as well as scientific gaps that hinder effective risk assessment. This track will highlight cutting-edge studies on how climate change, urbanization, and ecosystem shifts influence endocrine disorders at a population level, offering a multidisciplinary platform for scientists, clinicians, policy makers, and environmental health specialists to collaborate on actionable solutions.

This track focuses on the diagnosis, pathophysiology, and management of rare endocrine disorders that challenge conventional clinical approaches. Topics include rare genetic syndromes affecting glucose metabolism, unusual hormonal resistance disorders, rare pituitary or adrenal tumors, and metabolic abnormalities with atypical presentations. Attendees will explore how emerging molecular diagnostics, whole-genome sequencing, and precision medicine pathways are transforming our understanding and treatment of these conditions. The track also addresses limitations in existing guidelines due to the rarity of cases and emphasizes innovative diagnostic reasoning.

Case-based learning will be a major feature of this track, with clinicians presenting real-world complex endocrine scenarios that required unconventional strategies or multidisciplinary interventions. Participants will examine differential diagnostic workflows, biomarker-driven evaluations, and the role of advanced imaging in solving rare or atypical endocrine cases. Discussions will include challenges in global access, the importance of rare disease registries, and the need for collaborative networks to accelerate evidence generation. The goal is to empower clinicians with practical insights and to foster knowledge-sharing that improves real-life patient outcomes.

This track provides an in-depth exploration of surgical and interventional approaches for endocrine and metabolic disorders, bridging innovations in minimally invasive procedures, robotics, and image-guided interventions. Expert surgeons will present updated protocols for thyroidectomy, adrenalectomy, pancreatic endocrine tumor resections, and pituitary surgeries, highlighting precision techniques that reduce complications and ensure optimal hormonal balance postoperatively. Additionally, metabolic surgeries, including bariatric and metabolic bypass procedures, will be examined for their transformative impact on type 2 diabetes and cardiometabolic comorbidities.

Interventional endocrinology is an expanding field, and this track showcases procedures such as radiofrequency ablation, embolization techniques, selective venous sampling, and endoscopic interventions for tumor localization. Discussions will cover perioperative optimization for endocrine patients, postoperative hormonal management, and innovations in surgical imaging such as intraoperative fluorescence technology. By integrating clinical evidence, surgical videos, and expert insights, the track offers a comprehensive view of how advanced surgical strategies are reshaping modern endocrine care.

Designed as a hub for innovation, this track highlights the latest technologies, devices, diagnostics, and industry-led breakthroughs shaping the future of diabetes and endocrine care. Companies, innovators, and research teams will showcase new insulin delivery systems, wearable biosensors, AI-driven monitoring platforms, and advanced therapeutic molecules entering the clinical pipeline. Participants will gain insights into the engineering and scientific principles behind these innovations, as well as early-phase performance data from product trials.

The track also explores commercialization pathways, regulatory approval processes, and real-world adoption challenges for emerging technologies. Discussions will examine interoperability of devices, data security, patient usability, and health system integration. This is an ideal platform for clinicians seeking firsthand exposure to cutting-edge tools, industry leaders aiming to highlight novel solutions, and researchers interested in translational partnerships. The objective is to inspire collaboration between science and industry to accelerate impactful innovations that enhance patient outcomes.

This track is dedicated to empowering early-career investigators, graduate students, postdoctoral researchers, and young clinicians in endocrinology and metabolic science. Designed as an interactive learning environment, the forum includes sessions on research design, scientific writing, grant acquisition, publication strategies, and presentation skills. Participants will gain exposure to emerging research trends and learn how to position their work for maximum scientific and clinical impact. The track also provides insights into building a research career, navigating academic pathways, and establishing collaborations across institutions and countries.

A key highlight is the mentorship component, featuring guided small-group discussions, one-on-one mentoring opportunities, and career-building workshops led by senior faculty and global experts. Young researchers will have the chance to present abstracts, receive constructive feedback, and participate in award competitions. This track aims to nurture the next generation of leaders in endocrinology by providing them with the tools, support, and networks needed to excel in research, clinical practice, and health innovation.